SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?


To: LastShadow who wrote (23262)10/12/1999 8:58:00 AM
From: AlienTech  Respond to of 43080
 
Softbank, Murdoch's eVentures India To Be Running Soon
By Uday Lal Pai
India Correspondent, asia.internet.com
[October 11, 1999--MUMBAI] eVentures India, promoted by Media baron Rupert Murdoch and PK Mittal of Ispat Group of India, to focus on investments in Internet properties, will be operational soon.

The company will have equal equity stake from Ispat Group, US Internet venture capitalist Softbank and News Corp-prompted ePartners. Both Softbank and ePartners have a 50:50 stake in eVentures globally and it is eVentures, which will put in the money in the Indian venture. This means eVenture will own two-thirds of eVenture India.

"Our commitment, interest and belief in the Indian market is very high. We want to help support the amazing entrepreneurial community in India, which is showing an uncommon, touch for the new economy sweeping the world," Rupert Murdoch, chairman of News Corp said in a written statement.

"PK Mittal has been a good partner of ours and he brings a unique perspective to eVentures India" he added.

When contacted, Ispat group officials declined to reveal Mittal's monetary involvement, or the size of the initial corpus that eVentures India will set up saying the size was 'not very important.' Describing Mittal's foray into the Internet as a logical move, Vivek Seth, group finance director, Ispat said:"Internet and e-commerce are a thing of present and the future. Having seen a big opportunity in this field, we have tied up with the top names in the field."

The fund will identify high profile Indian ventures and assist them to grow into full potential with generous funding from Softbank(a wholly-owned subsidiary of Softbank Corporation of Japan in the USA) and ePartners (ePartners is headed by Mark Booth, acclaimed Net Guru). The alliance will offer cutting-edge technologies and business expertise to Internet ventures, aiming to develop ideas into full-blown and successful entities.

At the same time, the new venture will look at bringing to India at least half-a-dozen Internet companies owned by Softbank and Newscorp overseas. "By bringing the key US companies into Indian Internet market, we are laying the infrastructure for its future growth." said Softbank Corp chairman, Masayoshi Son in a separate statement.

In a parallel development, an Internet incubator focussing on leading edge start-ups namely 'Acquavit Inc' has merged with eVentures. Promoters of Acquavit Inc have been made partners of eVentures India.

According to Neeraj Bhargave, managing partner of Acquavit, the newly floated company had decided to forego all the money it was trying to raise to fund incubation services between the US-India corridor. The equity investment made by Acquavit in three ventures so far will be honourd by eVentures India, he added.

Incidentally, Murdoch's move comes on the heels of Subhash Chandra's (Chairman of Zee television, competitor of Murdoch's Star TV in India) announcement that E-Connect Limited, promoted by Zee and V Jindal, will be investing $100 million over the next three years to develop Net-related business in India.



To: LastShadow who wrote (23262)10/12/1999 9:01:00 AM
From: AlienTech  Read Replies (1) | Respond to of 43080
 
PPDI is down because the COO is leaving.. Guess no one here follows any CRO's..

HOW COULD YOU HAVE FOUND THIS DOUBLE?

Getting a drug approved for use in the U.S. can take 10 to 15 years and around $369 million. The CRO market has developed to serve the pharmaceutical and biotech firms in this arduous process that starts with pre-clinical testing, moves to human clinical trials, and ends (hopefully) with regulatory approval.

To reduce costs and expedite the development process, pharmaceutical and biotech firms now outsource an increasing amount of this work. Some industry sources suggest that about $40 billion was spent on drug-related R&D last year, with at least half of that of the sort provided by CROs. About $4 billion of this went to contract researchers.

PPD is one of a handful of large CROs conducting virtually the entire range of needed services. Though its revenue growth has trailed others in this consolidating sector, its size alone might have suggested that it would continue to benefit from the concurrent trends driving the creation of giant CROs.

At $12 1/4, the stock traded at less than 20 times trailing earnings, which is a bargain for a sector expecting long-term growth in the 20% to 25% range.

fnews.yahoo.com